Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Takeda says no to B7-H3
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
